This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GILD vs. HALO: Which Stock Is the Better Value Option?
by Zacks Equity Research
GILD vs. HALO: Which Stock Is the Better Value Option?
Puma Biotechnology, Inc. (PBYI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Bristol Myers (BMY) Gains 24.2% YTD: What's in Store for 2023?
by Zacks Equity Research
Biotech giant Bristol Myers (BMY) outperforms the industry and the S&P 500 Index as Eliquis and Opdivo maintain momentum despite generic competition for Revlimid.
The Zacks Analyst Blog Highlights Lowe's, Gilead Sciences, Intuitive Surgical, Valero Energy and MercadoLibre
by Zacks Equity Research
Lowe's, Gilead Sciences, Intuitive Surgical, Valero Energy and MercadoLibre are part of the Zacks top Analyst Blog.
Top Analyst Reports for Lowe's, Gilead Sciences & Intuitive Surgical
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Lowe's Companies, Inc. (LOW), Gilead Sciences, Inc. (GILD) and Intuitive Surgical, Inc. (ISRG).
Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?
by Zacks Equity Research
Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.
Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval
by Zacks Equity Research
Sanofi's (SNY) Enjaymo gets approval to treat hemolytic anemia in adult patients with cold agglutinin disease (CAD) in Europe.
Merck (MRK) Outpaces Industry YTD: What's in Store for 2023?
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023.
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales
by Zacks Equity Research
Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.
Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.
How Are Biotech ETFs Reacting to Q3 Earnings Releases?
by Sanghamitra Saha
Biotech earnings have come in upbeat in the third quarter.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '22 EPS View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down.
Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Nektar (NKTR) reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter.
Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
by Zacks Equity Research
Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
by Zacks Equity Research
TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook
by Zacks Equity Research
Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.
Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates
by Zacks Equity Research
Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.
Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.